Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arqule Reports First Quarter 2017 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2017. For the quarter ended March 31, 2017 , the Company reported a net loss of $7,576,000 or $0.11 per share, compared
View HTML
Toggle Summary ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 9,630,968. The patent claims composition of matter of ARQ 531. ArQule will be entitled to patent protection through December 2035 in the U.S.
View HTML
Toggle Summary ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter 2017 before the market opens on Wednesday, May 3, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
Plan to initiate a phase 1 trial by Q3 of 2017 BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application to conduct a phase 1 clinical trial
View HTML
Toggle Summary ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , M.D., Chief Medical Officer and Head of Research and Development, will present at the 16 th Annual Needham Healthcare Conference on April 4 th ,
View HTML
Toggle Summary ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan , and that the trial did not meet its primary endpoint of progression free survival (PFS).
View HTML
Toggle Summary ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016 , the Company reported a net loss of $6,820,000 or $0.10 per
View HTML
Toggle Summary ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year 2016 before the market opens on Tuesday, March 7, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
ArQule to host investor conference call on February 17, 2017 at 8:30 A.M. ET BURLINGTON, Mass. , TOKYO , MUNICH, & PARSIPPANY, N.J. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did
View HTML
Toggle Summary ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at The Leerink Partners 6 th Annual Global Healthcare Conference on
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.